Metabolism-regulated Ferroptosis in Cancer Progression and Therapy

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2024 Mar 8

PMID 38459004

Authors

Lvlan Ye

Xiangqiong Wen

Jiale Qin

Xiang Zhang

Youpeng Wang

Ziyang Wang

Ti Zhou

Yuqin Di

Weiling He

Affiliations

Soon will be listed here.

Abstract

Cancer metabolism mainly includes carbohydrate, amino acid and lipid metabolism, each of which can be reprogrammed. These processes interact with each other to adapt to the complicated microenvironment. Ferroptosis is a regulated cell death induced by iron-dependent lipid peroxidation, which is morphologically different from apoptosis, necrosis, necroptosis, pyroptosis, autophagy-dependent cell death and cuprotosis. Cancer metabolism plays opposite roles in ferroptosis. On the one hand, carbohydrate metabolism can produce NADPH to maintain GPX4 and FSP1 function, and amino acid metabolism can provide substrates for synthesizing GPX4; on the other hand, lipid metabolism might synthesize PUFAs to trigger ferroptosis. The mechanisms through which cancer metabolism affects ferroptosis have been investigated extensively for a long time; however, some mechanisms have not yet been elucidated. In this review, we summarize the interaction between cancer metabolism and ferroptosis. Importantly, we were most concerned with how these targets can be utilized in cancer therapy.

Citing Articles

NINJ1 in Cell Death and Ferroptosis: Implications for Tumor Invasion and Metastasis.

Chen S, Shyu I, Chi J Cancers (Basel). 2025; 17(5).

PMID: 40075648 PMC: 11898531. DOI: 10.3390/cancers17050800.

Ferroptosis in Pulmonary Disease and Lung Cancer: Molecular Mechanisms, Crosstalk Regulation, and Therapeutic Strategies.

Guo D, Cai S, Deng L, Xu W, Fu S, Lin Y MedComm (2020). 2025; 6(3):e70116.

PMID: 39991627 PMC: 11847630. DOI: 10.1002/mco2.70116.

Weight Management for Fertility-Preservation Therapy in Endometrial Cancer: Opportunities and Challenges.

Li X, Chen Y, Li X, Yang X, Zhou L, Cheng Y Curr Oncol Rep. 2025; .

PMID: 39913071 DOI: 10.1007/s11912-025-01635-9.

Deciphering the mechanisms of long non-coding RNAs in ferroptosis: insights into its clinical significance in cancer progression and immunology.

Ou S, Nie X, Qiu X, Jin X, Wu G, Zhang R Cell Death Discov. 2025; 11(1):14.

PMID: 39827195 PMC: 11743196. DOI: 10.1038/s41420-025-02290-6.

Immune imbalance in Lupus Nephritis: The intersection of T-Cell and ferroptosis.

Fan Y, Ma K, Lin Y, Ren J, Peng H, Yuan L Front Immunol. 2024; 15:1520570.

PMID: 39726588 PMC: 11669548. DOI: 10.3389/fimmu.2024.1520570.

References

Li C, Cui X, Li Y, Guo D, He S . Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in Hepatocellular Carcinoma. Sci Rep. 2023; 13(1):8681. PMC: 10227089. DOI: 10.1038/s41598-023-35796-z. View

Shen L, Zhang J, Zheng Z, Yang F, Liu S, Wu Y . PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. Int J Biol Sci. 2022; 18(14):5459-5474. PMC: 9461664. DOI: 10.7150/ijbs.74546. View

Zhang Q, Xiong L, Wei T, Liu Q, Yan L, Chen J . Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma. Oncogene. 2023; 42(19):1509-1523. DOI: 10.1038/s41388-023-02665-y. View

Patra K, Hay N . The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39(8):347-54. PMC: 4329227. DOI: 10.1016/j.tibs.2014.06.005. View

Ji L, Zhang Q, Cao Y, Liu L . A prognostic risk model, tumor immune environment modulation, and drug prediction of ferroptosis and amino acid metabolism-related genes in hepatocellular carcinoma. Hum Cell. 2023; 36(3):1173-1189. DOI: 10.1007/s13577-023-00885-8. View

Asantewaa G, Harris I . Glutathione and its precursors in cancer. Curr Opin Biotechnol. 2021; 68:292-299. DOI: 10.1016/j.copbio.2021.03.001. View

Qi H, Ning X, Yu C, Ji X, Jin Y, McNutt M . Succinylation-dependent mitochondrial translocation of PKM2 promotes cell survival in response to nutritional stress. Cell Death Dis. 2019; 10(3):170. PMC: 6382874. DOI: 10.1038/s41419-018-1271-9. View

Song X, Zhang W, Yu N, Zhong X . PAQR3 facilitates the ferroptosis of diffuse large B-cell lymphoma via the regulation of LDLR-mediated PI3K/AKT pathway. Hematol Oncol. 2023; 42(1):e3219. DOI: 10.1002/hon.3219. View

Chen M, Li X, Du B, Chen S, Li Y . Upstream stimulatory factor 2 inhibits erastin-induced ferroptosis in pancreatic cancer through transcriptional regulation of pyruvate kinase M2. Biochem Pharmacol. 2022; 205:115255. DOI: 10.1016/j.bcp.2022.115255. View

10.

Shin D, Lee J, You J, Kim D, Roh J . Dihydrolipoamide dehydrogenase regulates cystine deprivation-induced ferroptosis in head and neck cancer. Redox Biol. 2020; 30:101418. PMC: 6957841. DOI: 10.1016/j.redox.2019.101418. View

11.

Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J . Membrane Damage during Ferroptosis Is Caused by Oxidation of Phospholipids Catalyzed by the Oxidoreductases POR and CYB5R1. Mol Cell. 2020; 81(2):355-369.e10. DOI: 10.1016/j.molcel.2020.11.024. View

12.

Li Y, Yang W, Zheng Y, Dai W, Ji J, Wu L . Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res. 2023; 42(1):6. PMC: 9817350. DOI: 10.1186/s13046-022-02567-z. View

13.

Wang X, Xu B, Du J, Xia J, Lei G, Zhou C . Characterization of pyruvate metabolism and citric acid cycle patterns predicts response to immunotherapeutic and ferroptosis in gastric cancer. Cancer Cell Int. 2022; 22(1):317. PMC: 9563156. DOI: 10.1186/s12935-022-02739-z. View

14.

Yang J, Zhou Y, Li Y, Hu W, Yuan C, Chen S . Functional deficiency of succinate dehydrogenase promotes tumorigenesis and development of clear cell renal cell carcinoma through weakening of ferroptosis. Bioengineered. 2022; 13(4):11187-11207. PMC: 9278435. DOI: 10.1080/21655979.2022.2062537. View

15.

Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A . Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019; 566(7744):403-406. PMC: 6390935. DOI: 10.1038/s41586-019-0904-1. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Doll S, Proneth B, Tyurina Y, Panzilius E, Kobayashi S, Ingold I . ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2016; 13(1):91-98. PMC: 5610546. DOI: 10.1038/nchembio.2239. View

18.

Kotaka M, Gover S, Vandeputte-Rutten L, Au S, Lam V, Adams M . Structural studies of glucose-6-phosphate and NADP+ binding to human glucose-6-phosphate dehydrogenase. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 5):495-504. DOI: 10.1107/S0907444905002350. View

19.

Klasson T, LaGory E, Zhao H, Huynh S, Papandreou I, Moon E . ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma. Cancer Metab. 2022; 10(1):14. PMC: 9528056. DOI: 10.1186/s40170-022-00290-z. View

20.

Doll S, Porto Freitas F, Shah R, Aldrovandi M, Costa Da Silva M, Ingold I . FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019; 575(7784):693-698. DOI: 10.1038/s41586-019-1707-0. View